close

Global IT outage update - Monday 22 July

The issues affecting the supplier that provides our chemotherapy and immunotherapy treatments have now been resolved.

We want to thank our patients for being understanding and bearing with us and we apologise for any delays caused by this. Unless our teams contact you, please attend your appointment as planned. Throughout this incident, we have prioritised the most clinically urgent patients.

The Christie provides care and treatment for hundreds of people every day. The global IT outage last Friday (19 July 2024) affected many organisations but to put it into context, this affected less than a third of our patients.

Our staff have worked tirelessly over the weekend to deliver as many chemotherapy and immunotherapy treatments as possible and continue to do so to catch up on rescheduled treatments this week.

Skip to Content

Cutaneous lymphoma

The list below shows The Lymphoma Group's current clinical trials open for recruitment for cutaneous lymphoma patients.

If you would like to know how to access our trials, please see how to contact us.

  • StepPharma/STP938 - Testing STP938 in people with T-cell and B-cell lymphomas that has relapsed or is refractory
  • MOGAT - testing an innovative treatment schedule where mogamulizumab is used before Total Skin Electron Beam Therapy (TSEB) and then as a maintenance treatment in people with cutaneous T-cell lymphoma (CTCL).
  • BioInvent - testing a treatment called BI-1808 with or without Pembrolizumab in people with cutaneous T cell lymphoma. 


With special thanks to the following:

Lymphoma actionCRUKBloodwiseNCRI

For further information on each trial, please visit the Find a trial page on Lymphoma Action’s website.

Last updated: October 2023